B round financing with new and existing investors will advance GliaCure’s Alzheimer’s clinical program GliaCure, Inc., a company focused on developing novel, non-neuronal therapies for a range of neurological and neuropsychiatric disorders, today announced...
GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets.
GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture. (more)